Clinical Efficacy of High-flux Hemodialysis for Treating Uremia and its Effect on Microinflammation and Nutritional Status

Introduction. The objective of this study was to evaluate the clinical efficacy of high-flux hemodialysis for treating uremia and its effect on microinflammation and nutritional status.Methods. This was a case-control study. One hundred and twenty patients under chronic hemodialysis in Qinhuangdao Haigang Hospital from June 2021 to June 2023 were randomly divided into experiment group and control groups, with 60 patients in each group. Patients in the experiment group received high-flux hemodialysis (HFHD), while those in the control group underwent conventional hemodialysis. The differences between the two groups regarding clinical efficacy, inflammatory factors including IL-6, CRP and TNF-a, and macromolecular toxins including β2-microglobulin, parathyroid hormone, and cysteine protease inhibitor were compared. The levels of nutritional indices including serum transferrin, albumin, and hemoglobin were compared between the two groups after 6 months of therapy. All patients were followed- up for 1.5 to 2 years, and the incidence of their cardiovascular and cerebrovascular events after treatment was analyzed.Results. The response rate (markedly effective + effective)/total number of cases × 100%.) was 93% in the experiment vs. 80% in the control group (P = .03). After treatment, IL-6, CRP, TNF-a, β2-microglobulin, parathyroid hormone, and cysteine protease inhibitor significantly reduced and serum transferrin, albumin and hemoglobin significantly improved in the experiment vs. control group (P = .00). At the end of the follow-up period the incidence of cardiovascular and cerebrovascular diseases was 7% in the experiment group, which was markedly lower than that of 22% in the control group (P = .02).Conclusion. High-flux hemodialysis is a safe and effective treatment for uremia with remarkable clinical efficacy, offering various benefits such as significant reduction of inflammatory biomarkers and macromolecular toxins, improvement of patients’ nutritional status, and reduction of the incidence of cardiovascular and cerebrovascular diseases.

Authors

Publication Details

Journal
Journal of Kidney Diseases
Published
2025-08-15
DOI
https://doi.org/10.61882/ijkd.19.3.165
Primary Topic
Dialysis and Renal Disease Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Efficacy of High-flux Hemodialysis for Treating Uremia and its Effect on Microinflammation and Nutritional Status

Deheng Wan, Yan Wang, Jiakang Sun, Fei Guo
Journal of Kidney Diseases
Dialysis and Renal Disease Management
article

Clinical Efficacy of High-flux Hemodialysis for Treating Uremia and its Effect on Microinflammation and Nutritional Status

Deheng Wan, Yan Wang, Jiakang Sun, Fei Guo
article en

Abstract

Introduction. The objective of this study was to evaluate the clinical efficacy of high-flux hemodialysis for treating uremia and its effect on microinflammation and nutritional status.Methods. This was a case-control study. One hundred and twenty patients under chronic hemodialysis in Qinhuangdao Haigang Hospital from June 2021 to June 2023 were randomly divided into experiment group and control groups, with 60 patients in each group. Patients in the experiment group received high-flux hemodialysis (HFHD), while those in the control group underwent conventional hemodialysis. The differences between the two groups regarding clinical efficacy, inflammatory factors including IL-6, CRP and TNF-a, and macromolecular toxins including β2-microglobulin, parathyroid hormone, and cysteine protease inhibitor were compared. The levels of nutritional indices including serum transferrin, albumin, and hemoglobin were compared between the two groups after 6 months of therapy. All patients were followed- up for 1.5 to 2 years, and the incidence of their cardiovascular and cerebrovascular events after treatment was analyzed.Results. The response rate (markedly effective + effective)/total number of cases × 100%.) was 93% in the experiment vs. 80% in the control group (P = .03). After treatment, IL-6, CRP, TNF-a, β2-microglobulin, parathyroid hormone, and cysteine protease inhibitor significantly reduced and serum transferrin, albumin and hemoglobin significantly improved in the experiment vs. control group (P = .00). At the end of the follow-up period the incidence of cardiovascular and cerebrovascular diseases was 7% in the experiment group, which was markedly lower than that of 22% in the control group (P = .02).Conclusion. High-flux hemodialysis is a safe and effective treatment for uremia with remarkable clinical efficacy, offering various benefits such as significant reduction of inflammatory biomarkers and macromolecular toxins, improvement of patients’ nutritional status, and reduction of the incidence of cardiovascular and cerebrovascular diseases.

Journal of Kidney DiseasesVol. 19(03)
Openalex Percentile: Top 73%
Dialysis and Renal Disease Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinical Efficacy of High-flux Hemodialysis for Treating Uremia and its Effect on Microinflammation and Nutritional Status — Deheng Wan, Yan Wang, et al. · Journal of Kidney Diseases (2025) | TGRS Research Map | TGRS